Meet Denis
Denis Drygin, PhD, is a Biologist, Chemist, and Pharmacologist with over twenty years of experience in the discovery and development of RNA-targeting therapeutics. He has previously served in leadership positions at several biotech companies including Regulus Therapeutics, Cylene Pharmaceuticals, Nosis Biosciences and Jaan Biotherapeutics. In addition, Denis co-found Pimera Therapeutics, a clinical stage company focused on targeting RNA biogenesis for the treatment of advanced malignancies. During his career, Denis led or directly supervised the discovery and/or development of six therapeutics that entered clinical development including Farabursen, an oligonucleotide therapeutic, later acquired by Novartis. Dr. Drygin holds Bachelor’s and Master’s degrees in chemistry from Moscow State University, and later earned Masters and Doctorate degrees in Molecular Biology from the University of Massachusetts (UMASS), Amherst. He completed his post-doctoral training at Ionis Pharmaceuticals, where he served as a lead scientist investigating the pharmacology and toxicology of antisense oligonucleotides (ASOs).
At HAYA Therapeutics, Denis brings a unique combination of scientific depth and drug development expertise, strengthening our executional capabilities across R&D pipeline, ensuring an effective development from candidate selection through IND.
